retatrutide glp-1 gip glucagon Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA ✨ Retatrutide: The Next Evolution

Custom note concepts could include in-depth diet/nutritional information, behavioral interventions attempted for weight loss, as well as side effects from medication use

Why Families Choose Rixa Health Science-backed, compassionate, and designed for long-term results

FDA Label Update: October 2025 Plaintiffs argue these risks weren't adequately communicated

Strength work is the most powerful tool you have for maintaining metabolic rate during and after weight loss

Some studies have found that GLP-1 receptor agonist medications can 17: Improve ovulation and menstrual regularity Increase pregnancy rates in certain populations These effects appear to be largely mediated by: Improved insulin sensitivity Reduced androgen levels A more stable metabolic environment Cardiometabolic Health GLP-1 receptor agonists have consistently been shown to improve cardiometabolic risk markers